Darifenacin

Darifenacin

Clinical data
Trade names	Enablex
AHFS/Drugs.com	Monograph
MedlinePlus	a605039
Pregnancy category	AU: B3 US: C (Risk not ruled out)
Routes of administration	Oral
ATC code	G04BD10 (WHO)
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	15 to 19% (dose-dependent)
Protein binding	98%
Metabolism	Hepatic (CYP2D6- and CYP3A4-mediated)
Biological half-life	13 to 19 hours
Excretion	Renal (60%) and biliary (40%)
Identifiers
IUPAC name (S)-2-[1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl] pyrrolidin-3-yl] -2,2-diphenyl-acetamide
CAS Number	133099-04-4 Y
PubChem (CID)	444031
IUPHAR/BPS	321
DrugBank	DB00496 Y
ChemSpider	392054 Y
UNII	APG9819VLM Y
KEGG	D01699 N
ChEBI	CHEBI:391960 Y
ChEMBL	CHEMBL1346 Y
ECHA InfoCard	100.118.382
Chemical and physical data
Formula	C28H30N2O2
Molar mass	426.55 g/mol
3D model (Jmol)	Interactive image
SMILES O=C(N)C(c1ccccc1)(c2ccccc2)[C@H]3CN(CC3)CCc5cc4c(OCC4)cc5
InChI InChI=1S/C28H30N2O2/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26/h1-12,19,25H,13-18,20H2,(H2,29,31)/t25-/m1/s1 Y Key:HXGBXQDTNZMWGS-RUZDIDTESA-N Y
NY (what is this?)  (verify)

Darifenacin (trade name Enablex in US and Canada, Emselex in Europe) is a medication used to treat urinary incontinence. It was discovered by scientists at the Pfizer research site in Sandwich, UK under the identifier UK-88,525 and used to be marketed by Novartis. In 2010 the US rights were sold to Warner Chilcott for 400 million US$.

Mechanism of action

Darifenacin works by blocking the M₃ muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions. It thereby decreases the urgency to urinate. It is not known whether this selectivity for the M₃ receptor translates into any clinical advantage when treating symptoms of overactive bladder syndrome.

It should not be used in people with urinary retention. Anticholinergic agents, such as darifenacin, may also produce constipation and blurred vision. Heat prostration (due to decreased sweating) can occur when anticholinergics such as darifenacin are used in a hot environment.^[1]

Clinical uses

Darifenacin is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency in adults.

References

External links

• Enablex product website, run by Warner Chilcott